Polyol accumulation versus diabetic retinopathy and nephropathy in transgenic mice expressing human aldose reductase

  • Mitsuo Itakura
  • SetsukoII
  • Mika Ohta
  • Takashi Yamaoka
Part of the Rev.Ser.Advs.Research Diab.Animals (Birkhäuser) book series (RSARDA, volume 6)


Diabetes mellitus is caused by a relative or absolute insulin deficiency, and it affects >5% of the world’s population. Diabetic retinopathy is a leading cause of acquired blindness in adults, and diabetic nephropathy is a major cause of morbidity and mortality in diabetes.1,2 In a population study of 973 subjects, diabetic nephropathy was frequently associated with retinopathy.3 Of patients with diabetes, 18% (66 of 365) had proteinuria and 59% of those patients (39 of 66) had diabetic retinopathy. Of patients with proliferative diabetic retinopathy, 40% (19 of 47) had proteinuria. Of patients with preproliferative retinopathy, 16% (20 of 124) had proteinuria.4

Key words

transgenic mice aldose reductase diabetic complications nephropathy retinopathy galactose aldose reductase inhibitor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blom ML, Green WR, Schachat AP. Diabetic retinopathy: A review. Del Med J 66:379–88, 1994.PubMedGoogle Scholar
  2. 2.
    American Diabetes Association. Diabetes 1993 vital statistics. American Diabetes Association, Alexandria, VA, 1993.Google Scholar
  3. 3.
    West KM, Erdreich LJ, Stober JA. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 29:501–8, 1980.PubMedCrossRefGoogle Scholar
  4. 4.
    Jerneld B, Algvere P. Proteinuria and blood glucose levels in a population with diabetic retinopathy. Am J Ophthalmol 104:283–9, 1987.PubMedGoogle Scholar
  5. 5.
    Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 98:586–93, 1991.PubMedGoogle Scholar
  6. 6.
    Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: Possible evolutionary significance. Science 213:222–4, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Greene DA, Lattimer S, Ulbrecht J. Glucose-induced alterations in nerve metabolism: Current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 8:290–9, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    van Heyningen R. Formation of polyols by the lens of the rat with sugar cataract. Nature 184:194–5, 1959.CrossRefGoogle Scholar
  9. 9.
    Wilson DK, Bohren KM, Gabbay KH, Quiocho FA. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 257:81–4, 1992.PubMedCrossRefGoogle Scholar
  10. 10.
    Bateman JB, Kojis T, Heinzman C, et al. Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. Genomics 17:560–5, 1993.Google Scholar
  11. 11.
    Wang K, Bohren KM, Gabbay KH. Characterization of the human aldose reductase gene promoter. J Biol Chem 268:16052–8, 1993.PubMedGoogle Scholar
  12. 12.
    Garcia-Perez A, Burg MB. Renal medullary organic osmolytes. Physiol Rev 71:1081–115, 1991.PubMedGoogle Scholar
  13. 13.
    Smardo FL Jr, Burg MB, Garcia-Perez A. Kidney aldose reductase gene transcription is osmotically regulated. Am J Physiol 262:C776–82, 1992.PubMedGoogle Scholar
  14. 14.
    Burg MB. Molecular basis for osmoregulation of organic osmolytes in renal medullary cells. J Exp Zool 268:171–5, 1994.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferraris JD, Williams CK, Martin BM, et al. Cloning, genomic organization, and osmotic response of the aldose reductase gene. Proc Natl Acad Sci USA 91:10742–6, 1994.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakanishi T, Yamauchi A, Nakahama H, et al. Organic osmolytes in rat renal inner medulla are modulated by vasopressin VI and/or V2 antagonist. Am J Physiol 267:F146–52, 1994.PubMedGoogle Scholar
  17. 17.
    Grunewald RW, Weber II, Kinne-Saffran E, Kinne RK. Control of sorbitol metabolism in renal inner medulla of diabetic rats: Regulation by substrate, cosubstrate and products of the aldose reductase reaction. Biochim Biophys Acta 1225:39–47, 1993.PubMedGoogle Scholar
  18. 18.
    Bondy C, Cowley BD Jr, Lightman SL, Kador PF. Feedback inhibition of aldose reductase gene expression in rat renal medulla. J Clin Invest 86:1103–8, 1990.PubMedCrossRefGoogle Scholar
  19. 19.
    Kikkawa R, Umemura K, Haneda M, et al. Identification and characterization of aldose reductase in cultured rat mesangial cells. Diabetes 41:1165–71, 1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu RR, Lyons PA, Wang A, et al. Effects of galactose feeding on aldose reductase gene expression. J Clin Invest 92:155–9, 1993.PubMedCrossRefGoogle Scholar
  21. 21.
    Fabre S, Manin M, Pailhoux E, et al. Identification of a functional androgen response element in the promoter of the gene for the androgen-regulated aldose reductase-like protein specific to the mouse vas deferens. J Biol Chem 269:5857–64, 1994.PubMedGoogle Scholar
  22. 22.
    Donohue PJ, Alberts GF, Hampton BS, Winkles JA. A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase. J Biol Chem 269:8604–9, 1994.PubMedGoogle Scholar
  23. 23.
    Sato S, Lin LR, Reddy VN, Kado PF. Aldose reductase in human retinal pigment epithelial cells. Exp Eye Res 57:235–41, 1993.PubMedCrossRefGoogle Scholar
  24. 24.
    Sato S, Kador PF. Human kidney aldose and aldehyde reductases. J Diabetes Complications 7:179–87, 1993.PubMedCrossRefGoogle Scholar
  25. 25.
    Jörnvall H, Persson B, Krook M, Hempel J. Alcohol and aldehyde dehydrogenases. In: The molecular pathology of alcoholism. Palmer N, ed. Oxford University Press, Oxford, pp 130–56, 1991.Google Scholar
  26. 26.
    Lindstad RI, McKinley-McKee JS. Methylglyoxal and the polyol pathway. Three-carbon compounds are substrate for sheep liver sorbitol dehydrogenase. FEBS Lett 330:31–5, 1993.PubMedCrossRefGoogle Scholar
  27. 27.
    Vaca G, Ibarra B, Bracamontes M, et al. Red blood cell sorbito dehydrogenase deficiency in a family with cataracts. Hum Genet 61:338–41, 1982.PubMedGoogle Scholar
  28. 28.
    Estonius M, Danielsson O, Karlsson C, et al. Distribution of alcohol and sorbitol dehydrogenases: Assessment of mRNA species in mammalian tissues. Eur J Biochem 215:497–503, 1993.PubMedCrossRefGoogle Scholar
  29. 29.
    Kinoshita JH. Mechanisms initiating cataract formation. Invest Ophthalmol 13:713–24, 1974.PubMedGoogle Scholar
  30. 30.
    Stevens MJ, Lattimer SA, Kamijo M, et al. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 36:608–14, 1993.PubMedCrossRefGoogle Scholar
  31. 31.
    Stevens MJ, Henry DN, Thomas TP, et al. Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells. Am J Physiol 265:E428–38, 1993.PubMedGoogle Scholar
  32. 32.
    Sakakibara F, Hotta N, Koh N, Sakamoto N. Effects of high glucose concentrations and epalrestat on sorbitol and myoinositol metabolism in cultured rabbit aortic smooth muscle cells. Diabetes 42:1594–600, 1993.PubMedCrossRefGoogle Scholar
  33. 33.
    Haneda M, Kikkawa R, Arimura T, et al. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism 39:40–5, 1990.PubMedCrossRefGoogle Scholar
  34. 34.
    Yorek MA, Dunlap JA, Stefani MR, Davidson EP. Reduced Na+/K+ATPase transport activity, resting membrane potential, and bradykinin-stimulated phosphatidylinositol synthesis by polyol accumulation in cultured neuroblastoma cells. Neurochem Res 19:321–30, 1994.PubMedCrossRefGoogle Scholar
  35. 35.
    Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 16:383–91, 1994.PubMedCrossRefGoogle Scholar
  36. 36.
    Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Diabetes 43:1–8, 1994.PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas TP, Porcellati F, Kato K, et al. Effects of glucose on sorbitol pathway activation, cellular redox, and metabolism of myo-inositol, phosphoinositide, and di-acylglycerol in cultured human retinal pigment epithelial cells. J Clin Invest 93:2718–24, 1994.PubMedCrossRefGoogle Scholar
  38. 38.
    Kador PF, Akagi Y, Kinoshita JH. The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism 35:15–19, 1986.PubMedCrossRefGoogle Scholar
  39. 39.
    Wen Y, Bekhor I. Levels of expression of hexokinase, aldose reductase and sorbitol dehydrogenase genes in lens of mouse and rat. Curr Eye Res 12:323–32, 1993.PubMedCrossRefGoogle Scholar
  40. 40.
    Lee AYW, Chung SK, Chung SSM. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 92:2780–4, 1995.PubMedCrossRefGoogle Scholar
  41. 41.
    Ehrig T, Bohren KM, Prendergast FG, Gabbay KH. Mechanism of aldose reductase inhibition: Binding of NADP+/NADPH and alrestatin-like inhibitors. Biochemistry 33:7157–65, 1994.PubMedCrossRefGoogle Scholar
  42. 42.
    Tanaka Y, Suzuki A. Enzymatic hydrolysis of zenarestat 1-O-acylglucuronide. J Pharm Pharmacol 46:235–9, 1993.CrossRefGoogle Scholar
  43. 43.
    Sima AA. Structure-function interactions in the therapeutic response of diabetic neuropathy. J Diabetes Complications 6:64–8, 1992.PubMedCrossRefGoogle Scholar
  44. 44.
    Carrington AL, Ettlinger CB, Tomlinson DR. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: Effects of extracellular glucose concentration and of aldose reductase inhibition. J Diabetes Complications 8:33–9,1994.PubMedCrossRefGoogle Scholar
  45. 45.
    Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ. Effects of long-term aldose reductase inhibition on development of sural nerve in streptozocin-induced diabetic rats. Diabetes 39:690–6, 1990.PubMedCrossRefGoogle Scholar
  46. 46.
    Willars GB, Townsend J, Tomlinson DR, et al. Studies on peripheral nerve and lens in long-term experimental diabetes: Effects of the aldose reductase inhibitor statil. Metabolism 37:442–9, 1988.PubMedCrossRefGoogle Scholar
  47. 47.
    Sorbinil Retinopathy Trial Research Group. The sorbitol retinopathy trial: Neuropathy results. Neurology 43:1141–9, 1993.Google Scholar
  48. 48.
    Sima AA, Greene DA, Brown MB, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on polyneuropathy. The tolrestat study group. J Diabetes Complications 7:157–69, 1993.PubMedCrossRefGoogle Scholar
  49. 49.
    Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 108:1301–9, 1990.PubMedGoogle Scholar
  50. 50.
    Engerman RL, Kern T. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42:820–5, 1993.PubMedCrossRefGoogle Scholar
  51. 51.
    Chibber R, Molinatti PA, Wong JSK. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes 43:758–63, 1994.PubMedCrossRefGoogle Scholar
  52. 52.
    Engerman RL, Kern TS, Garment MB. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diabetes Complications 7:241–5, 1993.PubMedCrossRefGoogle Scholar
  53. 53.
    Chakrabarti S, Sima A A. Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Diabetes 38:1181–6, 1989.PubMedCrossRefGoogle Scholar
  54. 54.
    Vinores SA, Van-Niel E, Swerdloff JL, et al. Electron microscopic immunocyto-chemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. Exp Eye Res 57:723–35, 1993.PubMedCrossRefGoogle Scholar
  55. 55.
    Sorbitol Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108:1234–44, 1990.Google Scholar
  56. 56.
    Tilton RG, Chang K, Pugliese G, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38:1258–70, 1989.PubMedCrossRefGoogle Scholar
  57. 57.
    Watanabe T, Kawazu S, Katayama S, et al. A possible role of polyol pathway in diabetic nephropathy. Sakamoto N, Kinoshita JH, Kador PF, Hotta N, eds. Elsevier, Amsterdam, 1988, pp. 360–4.Google Scholar
  58. 58.
    Maleb ML, Sredy J, Millen J, et al. Prevention of urinary albumin excretion in 6 months streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabetes Complications 2:16–18, 1988.CrossRefGoogle Scholar
  59. 59.
    Pugliese G, Tilton RG, Speedy A, et al. Vascular filtration function in galactose-fed versus diabetic rats: The role of polyol pathway activity. Metabolism 39:690–7,1990.PubMedCrossRefGoogle Scholar
  60. 60.
    Chang WP, Dimitriadis E, Allen T, et al. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia 34:225–31, 1991.PubMedCrossRefGoogle Scholar
  61. 61.
    Tucker BJ, Rasch R, Blantz RC. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 92:686–94,1993PubMedCrossRefGoogle Scholar
  62. 62.
    Daniel BS, Hostetter TH. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 38:981–6, 1989.CrossRefGoogle Scholar
  63. 63.
    Mauer SM, Steffes MW, Azar S, et al. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes 38:839–46, 1989.PubMedCrossRefGoogle Scholar
  64. 64.
    Reddi AS, Jyothirmayi GN. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats. J Diabetes Complications 7:233–40, 1993.PubMedCrossRefGoogle Scholar
  65. 65.
    Pugliese G, Pricci F, Pugliese F, et al. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 43:478–90, 1994PubMedCrossRefGoogle Scholar
  66. 66.
    Kikkawa R. Aldose reductase inhibitor. Int Symp Prog Glomerulopathy (abs), 11, 1994.Google Scholar
  67. 67.
    Ranganathan S, Krempf M, Feraille E, Charbonnel B. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate and glomerular filtration rate in type 1 diabetic patients with incipient nephropathy. Diabetes Metab 19:257–61, 1993.Google Scholar
  68. 68.
    Win T, Asano G, Shimizu Y. The efficacy of aldose reductase inhibitor, antioxidant butylated hydroxytoluene and cysteine protease inhibitor E64 on hyperglycemia-in-duced metabolic changes in the organ-cultured bovine lens. J Nippon Med Sci Ika 61:180–9, 1994.Google Scholar
  69. 69.
    Matsui T, Nakamura Y, Ishikawa H, et al. Pharmacological profiles of a novel aldose reductase inhibitors, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol 64:115–24, 1994.PubMedCrossRefGoogle Scholar
  70. 70.
    Malamas MS, Hohman TC, Millen J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-l,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H),3’-pyrrolidine]-1,2’,3,5’(2H)-tetrone and congeners. J Med Chem 37:2043–58, 1994.PubMedCrossRefGoogle Scholar
  71. 71.
    Kato N, Mizuno K, Matsubara A, et al. Effect of long-term treatment with a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2’,5’-dioxospiro-[chroman-4,4’-imida-zolidine]-2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. J Diabetes Complications 8:27–32, 1994.PubMedCrossRefGoogle Scholar
  72. 72.
    Steele JW, Faulds D, Goa KL. Epalrestat a review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs Aging 3:532–55, 1993.PubMedCrossRefGoogle Scholar
  73. 73.
    Lindstad RI, Hermansen LF, Minley-Mee JS. Inhibition and activation studies on sheep liver sorbitol dehydrogenase. Eur J Biochem 221:847–54, 1994.PubMedCrossRefGoogle Scholar
  74. 74.
    Reiersen H, Lindstad RI, Minley-Mee JS. The inactivation of sheep liver sorbitol dehydrogenase by pyrophosphate and some analogous metal chelators. Arch Biochem Biophys 311:450–6, 1994.PubMedCrossRefGoogle Scholar
  75. 75.
    Tilton RG, Chang K, Nyengaard JR, et al. Inhibition of sorbitol dehydrogenase effect on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 44:234–42, 1995.PubMedCrossRefGoogle Scholar
  76. 76.
    Cohn RM, Segal S. Galactose metabolism and its regulation. Metabolism 22:627–42, 1973.PubMedCrossRefGoogle Scholar
  77. 77.
    Gabbay K, O’sullivan J. The sorbitol pathway in diabetes and galactosemia: Enzyme and substrate localization and changes in kidney. Diabetes 17:239–43, 1968.PubMedGoogle Scholar
  78. 78.
    Tilton RG, Pugliese G, Lose LS, et al. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats. J Diabetes Complications 5:230–7, 1991.CrossRefGoogle Scholar
  79. 79.
    Engerman RL, Kern TS. Hyperglycemia and development of glomerular pathology: Diabetes compared with galactosemia. Kidney Int 36:41–5, 1989.PubMedCrossRefGoogle Scholar
  80. 80.
    Kern TS, Engerman RL. Kidney morphology in experimental hyperglycemia. Diabetes 36:244–9, 1987.PubMedCrossRefGoogle Scholar
  81. 81.
    Cameron NE, Cotter MA. Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition. Eur J Pharmacol 243:47–53, 1993.PubMedCrossRefGoogle Scholar
  82. 82.
    Lorentz WB Jr, Shihabi ZK, Weidner N. Galactosemic nephropathy in the rat. Clin Physiol Biochem 5:261–7, 1987.PubMedGoogle Scholar
  83. 83.
    Yamaoka T, Nishimura C, Yamashita K, et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase NA. Diabetologia 38:255–61, 1995.PubMedCrossRefGoogle Scholar
  84. 84.
    Qi S, Akagi K, Araki K, et al. Rapid identification of transgenic mice with PCR amplification of DNA from ear punching. Methods Mol Cell Biol 2:119–22, 1991.Google Scholar
  85. 85.
    Ohta M, Ii S, Yamaoka T, et al. Galactose-induced albuminuria in transgenic mice expressing human aldose reductase. Nutr Res, 15:1343–53, 1995.CrossRefGoogle Scholar
  86. 86.
    Kador PF, Kinoshita JH. Diabetes and galactosemic cataracts. Ciba Found Symp 106:110–23, 1984.PubMedGoogle Scholar
  87. 87.
    Dethy JM, Callaert-Deveen C, Janssens M, Lenaers A. Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography. Anal Biochem 143:119–24, 1984.PubMedCrossRefGoogle Scholar
  88. 88.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–54, 1976.PubMedCrossRefGoogle Scholar
  89. 89.
    Elving LD, Bakkeren JAJM, Jansen MJH, et al. Screening for microalbuminuria in patients with diabetes mellitus: Frozen storage of urine samples decreases their albumin content. Clin Chem 35:308–10, 1989.PubMedGoogle Scholar
  90. 90.
    Ogino Y, Okada S, Ota Z. Effects of chronic, urea-induced osmotic diuresis on kidney weight and function in rats. Diabetologia 37:225–31, 1994.PubMedCrossRefGoogle Scholar
  91. 91.
    Tilton RG, Chang K, Pugliese G, et al. Inhibitors of aldose reductase block diabetes-induced increases in blood flow and GFR and markedly reduce 24 h urinary albumin excretion in the rat. Diabetes 36(Suppl 1):43A, 1987.Google Scholar
  92. 92.
    Beyer-Mears A, Ku L, Cohen MP. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes 33:604–7, 1984.PubMedCrossRefGoogle Scholar
  93. 93.
    Oates P, Williamson J, Chang K, et al. Attenuation of diabetes-induced vascular dysfunction by an inhibitor of sorbitol dehydrogenase (abs). Diabetes 43(Suppl):3,1994.Google Scholar

Copyright information

© Birkhäuser Boston 1996

Authors and Affiliations

  • Mitsuo Itakura
    • 1
    • 2
  • SetsukoII
    • 1
  • Mika Ohta
    • 1
  • Takashi Yamaoka
    • 1
  1. 1.Otsuka Department of Clinical and Molecular Nutrition, School of MedicineThe University of TokushimaTokushima, 770Japan
  2. 2.Otsuka Department of Clinical and Molecular Nutrition, School of MedicineThe University of TokushimaKuramoto-cho, Tokushima, 770Japan

Personalised recommendations